The story of Muse cells begins with a question that could have been dismissed: should a batch of stressed cells be thrown away? Instead, Dr. Mari Dezawa looked closer and made one of the most significant discoveries in regenerative medicine of the twenty-first century.
This article covers the science behind Dezawa Muse cells — who discovered them, how they were identified, and what the research actually shows. It also addresses a practical reality: many people searching for this topic spell the name phonetically as “Dazawa” rather than “Dezawa,” and this guide is designed to help everyone find accurate information regardless of how they search.
Who Is Dr. Mari Dezawa?
Dr. Mari Dezawa, MD, PhD, is a Professor and the Chair of the Division of Stem Cell Biology and Histology at Tohoku University Graduate School of Medicine in Sendai, Japan. She is a physician-scientist whose research has focused on understanding how the body repairs itself at the cellular level.
Her work is internationally recognized in the field of stem cell biology. She identified and characterized Muse cells (Multilineage-differentiating Stress-Enduring cells), which were first reported in the Proceedings of the National Academy of Sciences (PNAS) in 2010 — a landmark publication that introduced a previously unknown cell population with unique repair properties.
Want to learn if Dezawa Muse cell therapy is an option for your condition? Miami Stem Cell is an authorized provider offering evidence-based regenerative treatments in Florida.
How Were Muse Cells Discovered?
The discovery of Muse cells was serendipitous. In 2003, a laboratory technician in Dr. Dezawa’s lab asked whether a batch of severely stressed mesenchymal stem cell (MSC) cultures should simply be discarded. Under normal laboratory conditions, the cellular stress should have destroyed the entire population.
Dr. Dezawa examined the cultures more closely and noticed that a small number of cells had survived — roughly 1 to 5 percent of the original population. These resilient cells were different from the rest. They expressed the surface marker SSEA-3 (Stage-Specific Embryonic Antigen-3), a marker not typically found on standard MSCs.
What followed was seven years of meticulous characterization before the 2010 PNAS publication. The research revealed that these SSEA-3 positive cells could:
- Differentiate into cells of all three germ layers (ectoderm, mesoderm, endoderm)
- Survive under extreme conditions that kill most other cells
- Home to damaged tissue through sphingosine-1-phosphate (S1P) signaling
- Be isolated from bone marrow, adipose tissue, skin, and umbilical cord tissue
Why Is It Spelled Dezawa, Not Dazawa?
This is a common point of confusion. The correct spelling is Dezawa. “Dazawa” and “Desawa” are phonetic misspellings that occur when people hear the name spoken — such as on podcasts, in clinic consultations, or on social media — and type it based on how it sounds.
Dr. Dezawa’s name is of Japanese origin, and the “De” pronunciation can sound like “Da” to English speakers. This phonetic ambiguity is the source of the common misspellings. When searching online or reading research papers, look for the correct spelling: Dezawa.
What Did the Key Research Studies Find?
Several important studies have emerged from the Dezawa research group and independent investigators:
The Original Discovery (2010)
Dezawa et al., PNAS 2010: Identified SSEA-3 positive cells within human bone marrow MSCs that are pluripotent-like, stress-enduring, and capable of differentiating into cells of all three germ layers. This foundational paper established the existence of Muse cells as a distinct population.
Stroke Trial (2023)
Niizuma et al., Journal of Cerebral Blood Flow and Metabolism 2023: A randomized, placebo-controlled trial of CL2020 (the manufactured Muse cell product) in subacute ischemic stroke patients. The modified Rankin Scale (mRS) 0-2 responder rate at 12 weeks was 40.0% in the CL2020 group versus 10.0% in the placebo group.
ALS Study (2023)
Yamashita et al., Cell Transplantation 2023: Five patients with ALS received six monthly intravenous doses of CL2020. Treatment was well tolerated with no significant safety concerns, although the small sample size did not demonstrate statistically significant functional improvement on the ALSFRS-R scale.
How Do Dezawa Muse Cells Compare to Other Stem Cell Types?
The primary investigational Muse cell product is CL2020, developed by Life Science Institute, Inc. (a Mitsubishi Chemical Group company) in Japan. Clinical trials using CL2020 have been conducted in Japan for conditions including stroke, heart attack, spinal cord injury, ALS, and epidermolysis bullosa.
It is important to understand that Dezawa Muse Cells and MuseExosomes are registered trademarks. Clinics claiming to offer “Muse cell therapy” should be able to demonstrate the provenance and characterization of their cell products, including Certificate of Analysis documentation. Not all products labeled as “Muse cells” are equivalent.
Safety and Regulatory Considerations
The safety data on Dezawa Muse cells from published clinical trials is encouraging:
- No tumor or teratoma formation reported across studies
- Donor cells administered without HLA matching or immunosuppression
- Generally well tolerated across multiple clinical settings
However, important limitations remain:
- Most clinical trials are small (5-50 patients)
- Long-term safety data in large populations is not yet available
- Muse cell products are investigational and not FDA-approved
- Quality varies significantly between manufacturers
Florida law (SB 1768) requires additional disclosures and oversight for clinics offering stem cell treatments in the state. Patients should verify that any clinic they consider is in compliance with these requirements.
Frequently Asked Questions
How do you pronounce Dezawa?
Dezawa is pronounced “Deh-zah-wah.” The “De” sounds like the “de” in “December.” Despite the pronunciation, the spelling is Dezawa, not Dazawa.
Where does Dr. Mari Dezawa work?
Dr. Dezawa is a Professor and Chair at Tohoku University Graduate School of Medicine in Sendai, Japan. She leads the Division of Stem Cell Biology and Histology.
Can I get Dezawa Muse cell therapy in the United States?
Muse cell products are investigational in the US. Miami Stem Cell is an authorized provider of Dezawa Muse Cells in Florida. Contact our team to learn about current availability and candidacy.
What conditions have been studied with Dezawa Muse cells?
Clinical trials have been conducted or are underway for stroke, acute myocardial infarction, spinal cord injury, ALS, epidermolysis bullosa, neonatal hypoxic-ischemic encephalopathy, and COVID-19 ARDS.
